triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
=== 1960s === 1960: Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones" along with Roger Guillemin and Andrew V. Schally who received it "for their discoveries concerning the peptide hormone production of the brain". 1962: Katherine Johnson performed the calculations for the NASA orbital mission, launching John Glenn as the first person into orbit and returning them safely. 1963: Maria Goeppert Mayer became the first American woman to receive a Nobel Prize in Physics; she shared the prize with J. Hans D. Jensen "for their discoveries concerning nuclear shell structure” and Eugene Paul Wigner "for his contributions to the theory of the atomic nucleus and the elementary particles, particularly through the discovery and application of fundamental symmetry principles". She was born in Poland, but became a U.S. citizen in 1933. 1965: Sister Mary Kenneth Keller became the first American woman to earn a Ph.D. in Computer Science. Her thesis was titled "Inductive Inference on Computer Generated Patterns."
On July 2, 1992, John Crosbie, Canadian Federal Minister of Fisheries and Oceans, declared a two-year moratorium on the Northern Cod fishery, a designated fishing region off the coast of Newfoundland, after data showed that the total cod biomass had suffered a collapse to less than 1% of its normal value. The minister championed the measure as a temporary solution, allowing the cod population time to recover. The fisheries had long shaped the lives and communities on Canada's Atlantic eastern coast for the preceding five centuries. Societies which are dependent on fishing have a strong mutual relationship with them: the act of fishing changes the ecosystems' balance, which forces the fishery and, in turn, the fishing societies to adapt to new ecological conditions. The near-complete destruction of the Atlantic northwest cod biomass off the shores devastated coastal communities, which had been overexploiting the same cod population for decades. The fishermen along the Atlantic northwest had employed modern fishing technologies, including the ecologically devastating practice of trawling, especially in the years leading up to the 1990s, in the misguided belief that fishing stocks are perpetually plentiful and unable to be depleted. After this assumption was empirically and abruptly shown to be incorrect, to the dismay of government officials and rural workers, some 19,000 fishermen and cod processing plant workers in Newfoundland lost their employment.
yr) by detecting the 39K→38Ar→37Ar decay chain. Above the electroweak scale ΛEW (corresponding to the vacuum expectation value of the Higgs field, around 246 GeV), where Standard Model unification occurs, the three fundamental forces have comparable couplings, suggesting unification in Grand Unified Theories (GUTs). Historical models like Pati–Salam model (1973), unifying quarks/leptons and Georgi–Glashow model (1974), unifying all forces and particles/antiparticles, predict B violation via superheavy gauge bosons MX. The natural GUT energy scale ΛGUT is where SM gauge couplings converge, ~1015 GeV. This value is approximately thirteen orders of magnitude higher than the electroweak scale, or more than eleven orders of magnitude higher than the energy achievable in experiments conducted at particle accelerators. However, at these energies the estimation of proton decay lifetime is around 1029–1031 yr, within reach of dedicated experiments: when GUTs were proposed, the experimental limits were around 1030 yr (for decay modes which produce 𝜇 →𝑒 decays). These considerations strongly motivated proton decay searches. In 1981 was published the first limit by a water Cherenkov detector at the Homestake gold mine, looking for the production and detection of a decaying muon following a nucleon decay event:
=== Carcinogenicity === According to European Medicines Agency, formulations of trimebutine might be contaminated with N-nitrosamines. However, it was assigned CPCA Category 5 with acceptable daily intake of 1500 ng/day.
=== Notable faculty === Emily Anderson - first professor of German Nicholas Canny - historian Colm McDonald - professor of psychiatry Michael D. Higgins - sociologist, 9th President of Ireland William King - geologist Alice Perry - engineer Gerard Quinn - jurist, specialist in international and comparative disability law and policy Niamh Reilly - sociologist and political scientist George Johnstone Stoney - physicist
Sources: en.wikipedia.org
A third trial, Trial 3, was conducted during 2007–2008 in Gabon and Malawi. In Trial 1, the most common adverse reactions in participants with malaria treated with IV artesunate were acute renal failure requiring dialysis, hemoglobinuria and jaundice. The safety profile in Trial 2 was generally similar to Trial 1. One trial was used to evaluate both, safety and benefits of artesunate. The trial enrolled participants with severe malaria who needed hospitalization because of their condition. Participants received at random either artesunate or a medicine used to treat malaria (quinine). Participants and the health care providers knew which treatment was being given. The benefit of artesunate in comparison to quinine was evaluated by comparing the number of participants who died while in the hospital (in-hospital mortality). The benefit of artesunate was supported by the data from Trial 2 in which pediatric participants younger than 15 years of age with severe malaria were randomly assigned treatment with artesunate or quinine. The application for IV artesunate was granted priority review and orphan drug designations. The FDA granted approval of artesunate for injection to Amivas.
=== Mammals === Monogamous voles (such as prairie voles) have significantly greater density and distribution of vasopressin receptors in their brain when compared to polygamous voles. These differences are located in the ventral forebrain and the dopamine-mediated reward pathway. Peptide arginine vasopressin (AVP), dopamine, and oxytocin act in this region to coordinate rewarding activities such as mating, and regulate selective affiliation. These species-specific differences have shown to correlate with social behaviors, and in monogamous prairie voles are important for facilitation of pair bonding. When compared to montane voles, which are polygamous, monogamous prairie voles appear to have more of these AVP and oxytocin neurotransmitter receptors. It is important that these receptors are in the reward centers of the brain because that could lead to a conditioned partner preference in the prairie vole compared to the montane vole which would explain why the prairie vole forms pair bonds and the montane vole does not. As noted above, different species of voles vary in their sexual behavior, and these differences correlate with expression levels of vasopressin receptors in reward areas of the brain. Scientists were able to change adult male montane voles' behavior to resemble that of monogamous prairie voles in experiments in which vasopressin receptors were introduced into the brain of male montane voles.
On September 15, 2012, David Wood, Deputy Director of the EBU Technology and Development Department (who chairs the ITU working group that created Rec. 2020), told The Hollywood Reporter that South Korea plans to begin test broadcasts of 4K UHDTV next year. Wood also said that many broadcasters have the opinion that going from HDTV to 8K UHDTV is too much of a leap and that it would be better to start with 4K UHDTV. In the same article, Masakazu Iwaki, NHK Research senior manager, said that the NHK plan to go with 8K UHDTV is for economic reasons since directly going to 8K UHDTV would avoid an additional transition from 4K UHDTV to 8K UHDTV. On October 18, 2012, the Consumer Electronics Association (CEA) announced that it had been unanimously agreed by the CEA's Board of Industry Leaders that the term "Ultra High-Definition", or "Ultra HD", would be used for displays that have a resolution of at least 8 megapixels with a vertical resolution of at least 2,160 pixels and a horizontal resolution of at least 3,840 pixels. The Ultra HD label also requires the display to have an aspect ratio of 16:9 or wider and to have at least one digital input that can carry and present a native video signal of 3840 × 2160 without having to rely on a video scaler. Sony announced they would market their 4K products as 4K Ultra High-Definition (4K UHD). On October 23, 2012, Ortus Technology Co., Ltd announced the development of the world's smallest 3840 × 2160 pixel LCD panel with a size of 9.6 inches (24 cm) and a pixel density of 458 px/in.
The Bristol stool scale is a diagnostic medical tool designed to classify the form of human faeces into seven categories. It is used in both clinical and experimental fields. It was developed at the Bristol Royal Infirmary as a clinical assessment tool in 1997, by Stephen Lewis and Ken Heaton and is widely used as a research tool to evaluate the effectiveness of treatments for various diseases of the bowel, as well as a clinical communication aid; including being part of the diagnostic triad for irritable bowel syndrome.
Sources: en.wikipedia.org
== Stimulants == Stimulants directly affect the central nervous system, increasing blood flow and heart rate. These drugs primarily help athletes in complex team sports like basketball and association football as well as choreographed sports like figure skating and artistic gymnastics. Stimulants that are banned in competition only include amphetamines, beta-2 agonists, ephedrine, pseudoephedrine, fencamfamine, cocaine, methamphetamines, mesocarb, and other substances with similar chemical structures and biological effects, including the following:
Singapore was not greatly affected by the First World War (1914–1918), as the conflict did not spread to Southeast Asia. The only significant event during the war was the 1915 Singapore Mutiny by Muslim sepoys from British India, who were garrisoned in Singapore. After hearing rumours that they were to be sent to fight the Ottoman Empire, a Muslim state, the soldiers rebelled, killing their officers and several British civilians before the mutiny was suppressed by non-Muslim troops arriving from Johore and Burma.
No visible clubbing – Fluctuation (increased ballotability) and softening of the nail bed only. No visible changes in nails. Mild clubbing – Loss of the normal <165° angle (Lovibond angle) between the nailbed and the fold (cuticula). Schamroth's window (see image) is obliterated. Clubbing is not obvious at a glance. Moderate clubbing – Increased convexity of the nail fold. Clubbing is apparent at a glance. Gross clubbing – Thickening of the whole distal (end part of the) finger (resembling a drumstick) Hypertrophic osteoarthropathy – Shiny aspect and striation of the nail and skin Schamroth's sign or Schamroth's window test (originally demonstrated by South African cardiologist Leo Schamroth on himself) is a popular test for clubbing. When the distal phalanges (bones nearest the fingertips) of corresponding fingers of opposite hands are directly opposed (place fingernails of the same finger on opposite hands against each other, nail to nail), a small diamond-shaped "window" is normally apparent between the nailbeds. If this window is obliterated, the test is positive, and clubbing is present.
=== Post-synthetic modification === Although the three-dimensional structure and internal environment of the pores can be in theory controlled through proper selection of nodes and organic linking groups, the direct synthesis of such materials with the desired functionalities can be difficult due to the high sensitivity of MOF systems. Thermal and chemical sensitivity, as well as high reactivity of reaction materials, can make forming desired products challenging to achieve. The exchange of guest molecules and counter-ions and the removal of solvents allow for some additional functionality but are still limited to the integral parts of the framework. The post-synthetic exchange of organic linkers and metal ions is an expanding area of the field and opens up possibilities for more complex structures, increased functionality, and greater system control.
The building, at the cross sections of those streets that were once called Belascoaín, Carlos III, Fraternidad, and Pocito, is at 508 Avenida de Carlos III (English: Carlos III Avenue). To level the ground beneath the Temple, loads of soil and sand were brought in from each of the Six Provinces of Cuba and many of their major rivers; Camagüey Province, Havana Province, Las Villas Province, Matanzas Province, Oriente Province, and Pinar del Río Province.The building's cornerstone was laid on March 25, 1951, by Grand Master Carlos M. Piñero y del Cueto and the building's architect, Emilio Vasconcelos Frayde. Costs for the construction were made possible by voluntary donations donations from the Grand Lodge and Supreme Council of Cuba, and the Daughters of Acacia. A delegate from the Grand Lodge of Pennsylvania, upon seeing the Temple, wrote: "The cost of the temple was approximately US$4,000,000, and when we realize that there are but 31,700 Masons in Cuba, one can fully realize what a magnificent undertaking was brought to completion." On February 27, 1955, the National Masonic Temple of Cuba was officially inaugurated during the Third Inter-American Conference of Symbolic Freemasonry. At the consecration ceremony, Grand Master Carlos M. Piñeiro del Cueto said: "The consecration of the National Masonic Temple stands as a bulwark in the struggle for the freedom of all peoples and the dignity of mankind." At a height of eleven floors, it was at one time the second-tallest building on the entire island of Cuba.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.